Kornimate/medical-research-clean huggingface dataset:
efficacy of a desensitizing agent during at-home bleaching

Conditions: Sensitivity, Tooth

Summary: the main objective of this study is to evaluate if the use of ultraez during at-home bleaching treatment is effective in reducing tooth sensitivity, as well as doesn't affect the degree of tooth bleaching.

1. visit 1: study information and delivery of informed consent. recording of the patient's medical history, general examination, and prophylaxis. alginate impressions will be taken of the upper and lower arches for all patients who meet the inclusion criteria. the impressions will be poured into plaster, and individualized bleaching trays will be made for each patient. a positioning guide tray will be fabricated for color measurement. 2. visit 2: initial color measurement with a spectrophotometer and the positioning guide. each patient will receive their individualized trays. additionally, they will be given 3 syringes of bleaching agent (opalescence 16%, ultradent products) and one syringe of desensitizing agent (ultraez, ultradent products) or placebo (glycerin), according to their study group. both the desensitizing agent and placebo will be dispensed in identical syringes, coded as a and b, to ensure the blinding of the study; only the clinician responsible for randomization knows the coding. each patient will be provided with an instruction sheet and recording sheets to fill out daily during the 3-week study period. they will record the degree of dental sensitivity . 3. visit 3: first-week bleaching review. data collection (color + sensitivity). 4. visit 4: second-week bleaching review. data collection (color + sensitivity). 5. visit 5: third-week bleaching review and end of the study. data collection (color + sensitivity).

Eligibility criteria:
inclusion criteria: * no oral or systemic pathology * periodontally healthy * no cavities * tooth shade of the upper and lower canines a2 or darker exclusion criteria: * adhesive restorations or prostheses in the anterior region * enamel or dentin alterations * smoking * pregnant women * undergone prior bleaching treatment

Keywords: tooth bleaching vital bleaching desensitizing agents tooth sensitivity
extension study investigating the long-term safety of degarelix three-month depots in patients with prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this extension study was to collect long-term safety and tolerability information to support a marketing authorisation application for a three-month dosage regimen of degarelix.

the data include data from the participants who participated in both the main study fe200486 cs15 (nct00113753) and the extension study fe200486 cs15a.

Eligibility criteria:
inclusion criteria: * has given written consent prior to any study-related activity is performed. a study-related activity is defined as any procedure that would not have been performed during the normal management of the patient. * has successfully completed the main study. exclusion criterion: - has been withdrawn from the main study.

Keywords: prostate cancer androgen ablation therapy
effect of gongs mobilization with neuromuscular electrical stimulation vs conservative exercises among ac

Conditions: Adhesive Capsulitis

Summary: this study evaluates the effectiveness of gong's mobilization combined with neuromuscular electrical stimulation versus conservative exercises in improving range of motion, pain relief, and functional outcomes in patients with adhesive capsulitis.

using a randomized controlled design with 36 participants with estimated drop out 10% will be 40, the study will measure changes in active and passive shoulder mobility and spadi scores after 6 weeks.

Eligibility criteria:
inclusion criteria: * diagnosed cases of frozen shoulder confirmed by an orthopedician. * patients in stage ii or iii of adhesive capsulitis. * participants of both genders aged 41-60 years. * subjects with a restricted range of motion (rom), with losses of 25% or greater compared to the unaffected shoulder. exclusion criteria: * rotator cuff tears. * overuse injuries. * history of rheumatoid arthritis, osteoarthritis, or malignancies in the shoulder region. * adhesive capsulitis secondary to neurological disorders. * unstable shoulders or recurrent dislocations. * post-surgical cases involving the shoulder.
clinical study for topical lupeol in acne

Conditions: Acne

Summary: double-blind, randomized,4-week small-scale clinical trial for lupeol in the treatment of inflammatory and non-inflammatory acne lesions in split face fashion

to investigate the clinical efficacy and tolerability of lupeol for the treatment of facial acne, we conducted a small-scale, randomized, double-blinded, split-face clinical trial over the course of 4 weeks. fifteen of 16 enrolled patients completed the study, in which affected areas on half each patient's face were treated with 2% lupeol twice daily while the other side of the face was treated with a vehicle control. clinical visits were scheduled at baseline and at 2 and 4 weeks. the primary outcome of the study was the percent change in inflammatory lesions (papules, pustules, and nodules) at 4 weeks. the secondary outcomes were the percent change in non-inflammatory lesions (open and closed comedones) and the change in the leeds revised acne grading system score at 4 weeks. adverse events (aes) were defined as all unintended and harmful signs or symptoms; these were assessed by both patients' self-reporting and physicians' skin examination at each visit. results were analyzed using intent to treat (itt) groups. the per-protocol (pp) population consisted of the 15 patients who did not have any major protocol deviations. last observation carried forward (locf) analysis was used to evaluate the primary and secondary outcomes. \*\* randomization and blindness process \*\* at the time of initial presentation, an evaluation of acne severity was performed using both individual counts of inflammatory and non-inflammatory acne lesions and an assessment of the leeds revised acne grading system score. then, patients were randomly assigned to either left- or right-sided lupeol application, with the other side of the face assigned to vehicle-control application. a simple random allocation sequence was created using computer-based random number generators with a block size of 4. all dermatologists participating in outcome assessments, a physician assistant managing trial enrollment and administration, medical statisticians analyzing the data, and patients were blinded to the assignments. randomization codes were strictly secured in a safe in the administration office of the clinical research center until data entry was complete. the integrity of the blinding was ensured by packaging the study- and control products in identical tubes and by requiring a third party (other than the investigator/evaluator) to dispense the medication. in addition, both topical agents were identical in color and odor.

Eligibility criteria:
inclusion criteria: • patients over the age 15 years of age or older who were clinically diagnosed with mild to moderate acne vulgaris (leeds revised acne grading system score 2-7) exclusion criteria: • known pregnancy or lactation, any medical illness that might influence the results of the study, a previous history of oral acne medication or surgical procedures including laser treatment within 6 month and topical medication within 4 weeks of study enrollment.

Keywords: natural product clinical trial
molecular profiling of metastatic cancer in pleural effusion and ascites

Conditions: Metastatic Cancer

Summary: cancers are among the most frequent leading causes of death in taiwan, and many of them show their respective unique epidemiological and pathophysiological features in taiwanese population. one of the distinguishing features of cancers includes their potential to metastasize outside the primary tumor. pleural cavity and peritoneum are two of the most frequent sites of metastases when serosal surfaces are involved. the prognoses of such patients are extremely poor with a median survival of months. the understandings of cancer biology of tumor metastasis demand more in-depth studies at the molecular and cell levels. studies based on cell culture are excellent approaches for this purpose as the cell culture provides a relevant and renewable model for studying the pathological and molecular changes underlying human malignant tumors.

due to their easy accessibility, pleural effusions and ascites are two important clinical sources of metastatic cancer cells, which upon isolation, permit comparative studies between the biology nature of primary tumor and metastatic ones. in this study, we will try to isolate cancer cells from human malignant effusions, said to be pleural effusions and/or ascites. we will establish phenotypic alterations along the progression of malignant tumors with serosal metastasis, with special emphasis on expression of some proteases, laminin receptors and transcription factors involved in the process of invasion and metastasis. we would also perform clinical correlations, including tumor type, staging, status of lymph node metastasis and histopathological differentiation and grading, etc.

Eligibility criteria:
inclusion criteria: * cancer patients * pleural effusion or peritoneal effusion exclusion criteria: * infected and fever patients * anticoagulant treatment patients * patients don't attend this study

Keywords: metastatic cancer
impedance pneumography in assessment of asthma control in preschool children

Conditions: Wheezing; Asthma in Children

Summary: this study evaluates the value of impedance pneumography, used as overnight home recordings during a longitudinal design, in assessing asthma control in preschool children

lung function assessment of preschool children is hindered by their limited co-operation in conventional tests such as peak expiratory flow (pef) or spirometry. however, indices derived from spontaneous tidal respiratory air flow and the shape of tidal expiratory flow-volume and flow-time curves relate to lung function and are easier to record even in young children. as a more advanced approach, the time dynamics and complexity properties of the tidal breathing flow volume (tbfv) signal have been analysed and found to relate to various respiratory conditions. impedance pneumography (ip) is a method for measuring changes in the thoracic electrical impedance through skin electrodes, which varies as a function of lung aeration i.e. breathing. recent technical advancements have enabled ip to be used for accurate non-invasive tidal flow signal measurement. moreover, in overnight recordings at home, ip was found feasible for quantifying nocturnal tbfv variability in young children with lower respiratory symptoms, showing that preschool children with high risk of asthma present with increased variation of tidal flow profile shape, and momentarily lowered chaoticity, compared to children with lower risk of asthma. so far, there are no studies that have addressed the utility of ip to assess asthma control in young children with asthma. the purpose of this study is to investigate the utility of a commercially available ip device (ventica, icare finland, finland) and ip-derived clinical indices in assessing the clinical control of asthmatic children receiving normal therapy in a longitudinal setting. the primary hypothesis is that tbfv variability quantified by ip is associated with disease control during management of young children with asthma. the secondary hypothesis is that tbfv variability quantified by ip predicts changes in disease control during management of young children with asthma.

Eligibility criteria:
inclusion criteria: * age 4-7 years, both sexes * attending pediatric ward in the study centre due to asthmatic symptoms (wheeze, cough and/or dyspnea) * history and clinical signs allowing diagnosis of doctor diagnosed asthma and the need to start regular anti-asthmatic medication * signed informed consent exclusion criteria: * use of inhaled corticosteroid medication 30 days prior to study entry * other cardiorespiratory or neurological chronic diseases or states that may affect breathing * acute respiratory infection 2 weeks prior to study entry * chronic respiratory disorder of prematurity * implanted or external active medical devices

Keywords: impedance pneumography respiratory function asthma management
cerebrospinal fluid rhinorrhea after functional endoscopic sinus surgery

Conditions: Cerebrospinal Fluid Leakage

Summary: sinus surgery is a common procedure. a potential complication is injuring the membranes of the brain. this can lead to leakage of brain fluid through the nose. we would like to estimate the incident rates of that complication. at the end of the operation, a thin gauze is inserted into the nose on both sides in addition to the usual tampon. this gauze will be analyzed at the laboratory for beta-2-transferrin, which is a biomarker for brain liquid.

sinus surgery is a common procedure in rhinology for the treatment of chronic inflammation, tumors and other pathologies. these procedures are performed in the immediate vicinity of the skull base. the risk of injuring the membranes covering the brain in a way that requires further treatment is less than 1% \[ 1\]. such injuries to the skull base could lead to the loss of cerebrospinal fluid (csf). the destruction of the natural barrier raises the potential risk of ascending infections of the membranes and the brain itself from the nose. leakage of cerebrospinal fluid in the usually bloody surgical field of view is not always distinguishable and is sometimes only noticed postoperatively. the spontaneous closure of a leaky membrane of the brain without further surgical treatment is known. this is why small traumata in the skull base often remain undetected. at the end of the operation, a thin gauze is inserted into the nose on both sides in addition to the usual tampon. the tampon and the additional gauze are removed the day after the operation and will be sent with a tube of venous blood to the laboratory. the gauze and the venous blood will be checked for beta-2-transferrin, which is a biomarker for cerebrospinal fluid. during further clinical standard controls will the patient be asked about symptoms of fluid leak through the nose. if positive, regardless to this study, the patient must have an additional ct scan of the sinuses and another blood sample checking for beta-2-transferrin.

Eligibility criteria:
inclusion criteria: * all patients with planned sinus surgery in terms of ethmoidektomie / sphenoethmoidektomie or frontosphenoethmoidektomie * male and female patients aged 18 to 99 years * written consent of the participating person after the enlightenment exclusion criteria: * olanned or accidental opening of the skull base * tumor in the skull base * pre-existing known rhinoliquorrhoe * lack of understanding the study or investigation
the ischemia modified albumin in diagnosing ischemic new events

Conditions: Heart Disease, Ischemic; Ischemia, Myocardial; Ischemic Heart Disease; Unstable Angina

Summary: the purpose of the study is to evaluate the utility of ischemia modified albumin (ima) for risk stratification in patients presenting with chest discomfort and possible ischemic heart disease, and to evaluate the diagnostic and prognostic implication for ima for major adverse cardiac events.


Eligibility criteria:
inclusion criteria: * patients with primary complaints of chest discomfort or patients with symptoms indicative of a moderate to high probability for unstable angina clinically indicated reason for evaluation for acs in the emergency department meeting tyhe following inclusion criteria will be enrolled: * age \>=21 years * presentation within two hours of relief of most recent episode of chest pain or presence of on-going symptoms suggestive of coronary ischemia, which should be at least 10 minutes in duration. * patients being evaluated for suspected ischemic signs and or symptoms (chest pain) at the time of presentation according to routine standard of care institutional chest pain protocol/pathway. exclusion criteria: * administration of thrombolytic medication prior to first (presentation) blood draw * acute coronary syndrome (acs) secondary to supply/demand inequity (i.e. known anemia, tachycardia, - defined as hr greater than 150 bpm, known sepsis, hypotension, defined as blood pressure \< 90 mmhg). * established diagnosis of liver cirrhosis * other acute ischemic sources (ongoing severe claudication, mesenteric ischemia, acute tia/cva) * renal failure requiring dialysis * greater than 2 hours from relief of the most recent episode of chest pain or signs and symptoms suggestive of coronary ischemia. * chest pain following traumatic injury to the chest * evidence for sever systemic infection, manifesting as fever (temperature \>100 degrees) and systolic blood pressure \<100 mmhg * patients unwilling or unable to provide written consent, without available next of kin * cocaine-related chest pain * pregnancy * known diagnosis of active malignancy * acute bowel ischemia * severe peripheral vascular disease * acute brain ischemia

Keywords: myocardial ischemia chest pain ischemia modified albumin acute coronary syndrome
neurofeedback training for older adults with mild cognitive impairment: a protocol study

Conditions: Mild Cognitive Impairment

Summary: this is a non-pharmacological study evaluating the effects of smr/delta ratio and beta1/theta ratio neurofeedback trainings on cognitive performance and electrical brain activity in elderly with mild cognitive impairment.

older adults with mild cognitive impairment (mci) are at high risk to progress to alzheimer's disease (ad). slowing down effect of dementia by enhancing brain plasticity represents one of the most prominent challenges. neurofeedback is one of the promising techniques that showed therapeutic efficacy and cognitive improvement in attention-deficit hyperactivity disorder, epilepsy, stroke. we aim to study the effects of two neurofeedback training protocols, smr/delta ratio and beta1/theta ratio, on cognitive performances in older adults with mild cognitive impairment and to assess whether mci patients change in brain electrical activity in a resting state after training.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild cognitive impairment * mmse score \>24 * subjective memory complaint confirmed by an informant. * perform at/or below 1.5 standard deviations from the mean for age and education-matched norms on more than one of the neuropsychological tests. * preserve activity of daily living * absence of dementia. exclusion criteria: * psychiatric and neurological disorders * history of alcohol or other substance consumption

Keywords: mild cognitive impairment neurofeedback electroencephalography attention memory
safety and tolerability of z-100 in patients with early hiv infection

Conditions: HIV Infections

Summary: the purpose of the study is to see if z-100 (an investigational drug) treatment is safe in hiv patients who have never received treatment for their hiv, who have not been taking highly active antiretroviral therapy (haart) for at least 8 weeks, or who have been stable on their current first or second haart regimen for at least 12 weeks.


Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv positive but do not show symptoms. * are male or female, 18 years or older. * have not received treatment for hiv. * have received treatment but have discontinued haart for at least 8 weeks prior to screening, have had stable viral loads on at least 2 separate time points at least 1 month apart including screening, and have had stable cd4 levels on at least 2 separate time points at least 1 month apart including screening. * use birth control while on the study and during the follow-up period. * have viral loads of 2,000 to 55,000 copies/ml within 2 weeks of randomization. * have cd4 counts of greater than 350 cells/mm within 2 weeks of randomization. * have a negative serum pregnancy test within 2 weeks of randomization (women able to have children). exclusion criteria patients will not be eligible for this study if they: * have failed haart treatment. * have opportunistic infection or cancer. * have a history of tuberculosis. * have very abnormal laboratory test results. * have heart, liver, kidney or nervous system conditions. * have serious problems digesting and absorbing food or have serious long-term diarrhea within 4 * weeks of randomization. * have received radiation (localized is allowed) or chemotherapy within 30 days before randomization. * have seizure disorders that cannot be controlled. * have received any other drugs that affect the immune system or experimental drugs within 60 days before randomization. * have had any vaccination within 15 days before randomization. * have a mental condition which makes the patient unable to understand what the study is about and what it involves. * have a history of alcohol or drug abuse, unless the investigator feels that it will not interfere with participation in the protocol. * are pregnant or breast-feeding. * have a history of being very sensitive to the study drug or similar drugs.

Keywords: drug tolerance acute infection
peripheral electrical stimulation for the treatment of overactive bladder

Conditions: Idiopathic Overactive Bladder

Summary: this clinical trial testing three different sites of transcutaneous electrical nerve stimulation for the treatment of overactive bladder (oab).


Eligibility criteria:
inclusion criteria: * males and females, at least 18 years of age * documented symptoms of idiopathic overactive bladder for at least 3 months * failure on primary oab treatment, such as behavior modification or fluid/diet management * patients can remain on stable medication * willing and capable of understanding and complying with all requirements of the protocol * signed informed consent to participate in the study after full discussion of the research nature of the treatment and its risks and benefits exclusion criteria: * urinary retention or post voiding residual greater than 100 ml * clinically significant bladder outlet obstruction * stress predominant mixed urinary incontinence * neurological disease affecting urinary bladder function, including but not limited to parkinson's disease, multiple sclerosis, stroke, spinal cord injury. * pelvic surgery (such as sub-urethral sling, pelvic floor repair) within the past 6 months * denovo oab following pelvic surgery sub-urethral sling intravesical or urethral sphincter botulinum toxin type a injections within the past 6 months * percutaneous tibial nerve stimulation (ptns) therapy for overactive bladder within the past 6 months * any form of electric stimulation to the pelvis or lower limbs within 4 weeks * vaginal prolapse greater than stage ii in the anterior compartment of the vagina using international continence society (ics) pelvic organ prolapsequantification (popq) criteria. * prior periurethral or transurethral bulking agent injections for bladder problems within the past 12 months. * history of pelvic radiation therapy * any skin conditions affecting treatment sites * lacking dexterity to properly utilize the components of the stimulator system. * presence of an implanted electro-medical device (e.g. pacemaker, defibrillator, interstim®, etc.), * pregnant, nursing, suspected to be pregnant (by urine pregnancy method), or plans to become pregnant during the course of the study. * recurrent urinary tract infections uti (\>3 uti's in the past year) * history of, or current, lower tract genitourinary malignancies * any clinically significant systemic disease or condition that in the opinion of the investigator would make the patient unsuitable for the study * any other clinical trial within 6 months

Keywords: overactive bladder transcutaneous posterior tibial nerve stimulation placebo ptns